Donate to HSC
Donate to HSC
Facebook
Twitter
Instagram

BioMarin is a global pharmaceutical company with more than 20 years of experience in developing medicines for rare genetic conditions.

BioMarin is pleased to update the community regarding our ongoing gene therapy clinical trial program in
hemophilia A. BioMarin’s investigational gene therapy for hemophilia A has not been approved for use; it is
in ongoing clinical trials evaluating its safety and efficacy.

Read the whole article here.